The objective of dosimetry is to guide the design and implementation of radiopharmaceutical therapy, either on a patient population basis, or if the variability is sufficiently high, on an individual patient basis. Key to this is that absorbed dose estimates predict likely toxicity and tumor response to treatment. It is not possible to administer a tracer level of activity in alpha-particle emitter therapy to obtain the pharmacokinetics required for dosimetry, therefore, preclinical microscale dosimetry studies must be combined with macroscopic whole-organ dosimetry. We illustrate this approach for an antibody that targets the immune checkpoint inhibitor, PD-L1 which we have investigated as a means of alpha-particle emitter delivery in a combined immunological and alpha-particle emitter targeting strategy.
JOSEFSSON Anders;
NEDROW Jessie;
HOBBS Robert F.;
BAECK Tom;
PARK Sunju;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
SGOUROS George;
2017-08-01
European commision - Joint Research Centre
JRC106151
http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/,
https://publications.jrc.ec.europa.eu/repository/handle/JRC106151,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|